NCT00006373View on ClinicalTrials.gov

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

February 29, 2000

Primary Completion Date

October 31, 2006

Study Completion Date

December 31, 2011

Conditions
Lymphoma
Interventions
DRUG

etoposide

Etoposide IV 500 mg/m2/day over 24 hours Days -5, -4, -3

DRUG

ifosfamide

Ifosfamide 3,333 mg/m2/day IV over 2 hours (total dose 10,000 mg/m2)Days -8, -7, -6

DRUG

topotecan hydrochloride

Topotecan 21.3 mg/m2/day (total dose 64 mg/m2 ) IV over 30 minutes Days -8, -7, -6

PROCEDURE

autologous bone marrow transplantation

DRUG

Mesna

Mesna 1,111 mg/m2/dose IV over 30 minutes; 30 minutes before and 4 and 8 hours after ifosfamide (total dose 10,000 mg/m2) Days -8, -7, -6

Trial Locations (1)

33612-9497

H. Lee Moffitt Cancer Center and Research Institute, Tampa

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT00006373 - Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter